Replies to post #21072 on Ayala Pharmaceuticals Inc (ADXS)

[Traderbx]

The reason BMS is making that statement is because BMS Opdivo just failed a trial in lung cancer and MERK got a One up BMS....

So BMS Opdivo is fading market expectations and MERK keytruda is gaining market expectations....

“Combining immunotherapy agents is at the core of Bristol-Myers Squibb’s strategy, as it brings the opportunity to improve anti-tumor efficacy,”